Work

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Year: 2017
Type: article
Abstract: OBJECTIVE: Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. DESIGN: Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test. RESULTS: After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment. CONCLUSIONS: In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other. TRIAL REGISTRATION NUMBER: EudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-results.
Source: Gut
Institutions: Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Nantes, Nantes Université, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Hôpital Beaujon, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau, Université de Rouen Normandie, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Hôpital Purpan, Hôpital Paule de Viguier, Hôpital de La Grave, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Hôpital Saint-Antoine, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Cliniques Universitaires Saint-Luc, Hospital Universitario Ramón y Cajal, Centre Hospitalier Universitaire Amiens-Picardie, Lille Inflammation Research International Center, Bicêtre Hospital, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Louis-Mourier, Centre Hospitalier Universitaire de Saint-Étienne, Universitair Ziekenhuis Leuven, University Hospital Mútua de Terrassa, Mútua Terrassa, Universitat de Barcelona, University of Helsinki, Helsinki University Hospital, Hospital Universitario de La Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Groupe Hospitalier Intercommunal Le Raincy Montfermeil, Ghent University Hospital, Inserm, Sorbonne Paris Cité, Centre de Recherche Épidémiologie et Statistique, Centre Hospitalier Universitaire de Liège
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2569748522
FWCI: 15.32
Cites: 21
Cited by: 180
Related to: 10